Ministry of Health Registers Original Biocad Drug for Systemic Scleroderma

The Ministry of Health of the Russian Federation has approved the use of divozilumab, developed by Biocad, for a new indication – systemic scleroderma.

Originally developed for multiple sclerosis, divozilumab becomes the first original genetically engineered biological drug for systemic scleroderma registered in Russia. More than 160 patients from Russia and Belarus participated in clinical trials. After 48 weeks of treatment, significant improvements were observed in skin pathology, such as reduced swelling and hardening. A reduction in disease-specific antibody levels was also noted.